Startup profile · funding coverage
Thyme Care
Thyme Care partners with payers and providers on value-based oncology navigation and care management.
Stage
See coverage
Status
private
Coverage
full
Why Thyme Care is interesting
Cancer care coordination is a proven VBC wedge; a16z Bio+Health backed through unicorn Series D as Thyme manages $5B+ in oncology spend.
Key facts
- Series C (Jul 2024): $55M equity; a16z Bio+Health among existing investors — Thyme Care blog
- Series D (Sep 2025): $97M; CVS Health Ventures, a16z Bio+Health, AlleyCorp participated — Fierce Healthcare
- Value-based oncology navigation platform
Investors in our directory
Funds linked from Thyme Care's profile — open a fund page for stage focus and related deal articles.
Industries
Healthtech Biotech & Life Sciences
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
FAQs about Thyme Care
Funding context and why this company shows up in venture coverage.
Thyme Care is listed among Andreessen Horowitz (a16z) investments on a16z’s public investment list.
We track a16z-backed companies that are strategically relevant for founders and investors following AI, American Dynamism, crypto, bio, and enterprise software.
Last updated: 2026-07-24